<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02031939</url>
  </required_header>
  <id_info>
    <org_study_id>2013013</org_study_id>
    <secondary_id>SYSU5010Fund</secondary_id>
    <nct_id>NCT02031939</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer</brief_title>
  <official_title>Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although neoadjuvant chemoradiotherapy has significantly reduced the risk of local recurrence
      in locally advanced rectal cancer, systemic failure remains a predominant issue probably due
      to the insufficient control of systemic micro-metastasis in the neoadjuvant treatment.
      Induction chemotherapy is one of the most studied strategies. However, the efficacy of
      induction chemotherapy prior to neoadjuvant chemotherapy remains controversial. In our
      previous study, induction chemotherapy, gap chemotherapy combined with neoadjuvant
      chemoradiotherapy can improve response rate of rectal cancer patients, but the results have
      not been confirmed in clinical trial. Whether this new kind of treatment can optimize
      neoadjuvant therapy for locally advanced rectal cancer or not is still a big problem in
      clinical practice. This study will focus on how to optimize neoadjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respond rate</measure>
    <time_frame>One week after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">556</enrollment>
  <condition>Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Standard chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard chemoradiotherapy (Capecitabine 825mg/m2 combined with radiotherapy )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>induction and gap chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>induction chemotherapy (Capecitabine 2000mg/m2 +oxaliplatine 130mg/m2) + standard chemoradiotherapy (Capecitabine 2000mg/m2 combined with radiotherapy) + gap chemotherapy (Capecitabine 2000mg/m2 + oxaliplatine 130mg/m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction and gap chemotherapy (Capecitabine combine with oxaliplatin)</intervention_name>
    <description>All rectal cancer patients in this group will receive induction, gap chemotherapy(capecitabine combine with oxaliplatin) alone with standard chemoradiotherapy before surgery.</description>
    <arm_group_label>induction and gap chemotherapy</arm_group_label>
    <other_name>Xeloda</other_name>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>standard chemoradiotherapy</intervention_name>
    <description>All rectal patients in this group will receive standard chemoradiotherapy and surgical resection.</description>
    <arm_group_label>Standard chemoradiotherapy</arm_group_label>
    <arm_group_label>induction and gap chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathological confirmed rectal cancer

          -  Clinical stage T3-4 or T any N1

          -  No metastasis

          -  Distance of tumor is no more than 10cm from anal verge

          -  No previous radiotherapy

          -  Age ranged from 18 to 70

          -  Eastern Cooperative Oncology Group score system 0-1

        Exclusion Criteria:

          -  Clinical stage T1-2 N0

          -  Distance metastasis

          -  Multiple primary tumor

          -  Cachexy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen-Hai Lu, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhen-Hai Lu, Prof.</last_name>
    <phone>+86 20 87343584</phone>
    <email>luzhh@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rong-Xin Zhang, M.D.</last_name>
    <phone>+86 20 87343456</phone>
    <email>zhangrx@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhen-Hai Lu, Prof.</last_name>
      <phone>+86 20 87343584</phone>
      <email>luzhh@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Rong-Xin Zhang, M.D.</last_name>
      <phone>+86 20 87343456</phone>
      <email>zhangrx@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Zhen-Hai Lu, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rong-Xin Zhang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fu-Long Wang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuan-Hong Gao, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Jing Fang, PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiao-Jun Wu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhi-Zhong Pan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gong Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pei-Rong Ding, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhi-Fan Zeng, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun-Zhong Lin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qing Liu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>De-Sen Wan, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2013</study_first_submitted>
  <study_first_submitted_qc>January 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2014</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhen-Hai Lu</investigator_full_name>
    <investigator_title>Pofessor</investigator_title>
  </responsible_party>
  <keyword>Rectal cancer</keyword>
  <keyword>neoadjuvant chemoradiotherapy</keyword>
  <keyword>optimization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

